Related Experiment Video
Updated: Aug 15, 2026
10:01
Structure-Guided Design and Development of Novel Cyclophilin A Inhibitors and Ganoderiol-F Derivatives: An In-Silico Approach
Published on: June 23, 2026
Design of Inhibitors for S100B
Joseph Markowitz1, Alexander D Mackerell, France Carrier
1University of Maryland School of Medicine, Department of Biochemistry and Molecular Biology, Maryland 21201, USA.
Current Topics in Medicinal Chemistry
|October 27, 2005
Summary
Inhibiting the S100B protein
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- S100B protein negatively regulates the tumor suppressor activity of p53.
- Elevated S100B levels are observed in cancers like malignant melanoma.
- The S100B-p53 interaction is calcium-dependent.
Purpose of the Study:
- To explore the inhibition of the S100B-p53 interaction as a novel cancer therapy.
- To restore the tumor suppressor function of wild-type p53 in S100B-expressing cancers.
Main Methods:
- Computational techniques for drug discovery.
- Structural biology methods to analyze protein interactions.
- Cellular assays to validate compound efficacy.
Main Results:
- The abstract presents a discussion of the biological rationale for targeting S100B.
- Methodologies for discovering S100B-p53 inhibitors are described.
Conclusions:
- Targeting the S100B-p53 interaction offers a promising strategy for cancer treatment.
- Further research into S100B inhibitors could lead to new therapeutic approaches for melanoma and other cancers.
